Pathophysiology of benign prostatic hyperplasia in the aging male population
- PMID: 16986052
- PMCID: PMC1477609
Pathophysiology of benign prostatic hyperplasia in the aging male population
Abstract
Nearly all men will develop histological benign prostatic hyperplasia by the age of 80, but the degree of prostatic enlargement resulting from the hyperplasia is highly variable. Historically, it has often been assumed that the pathophysiology of lower urinary tract symptoms (LUTS) in men is the result of bladder outlet obstruction associated with prostatic enlargement. The observation that prostatic enlargement, bladder outlet obstruction, and LUTS are all age-dependent has been interpreted to indicate that these phenomena were causally related, but there is insufficient evidence for this. Undoubtedly, some men' prostatic enlargement causes obstruction and symptoms. Based upon the available data, however, this subset appears to be extremely small. Because of the many urological and nonurological conditions that cause LUTS and age-dependent changes in bladder and neurological function, it is unlikely that there exists a single dominant etiology for the aging male population. If this is the case, then the optimal management of LUTS will require different and possibly combination therapies.
Figures
Similar articles
-
Pathophysiology of lower urinary tract symptoms in the aging male population.Rev Urol. 2005;7 Suppl 7(Suppl 7):S3-S11. Rev Urol. 2005. PMID: 16986059 Free PMC article.
-
Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia.Rev Urol. 2004;6 Suppl 9(Suppl 9):S3-S10. Rev Urol. 2004. PMID: 16985922 Free PMC article.
-
Pathophysiology of benign prostate enlargement and lower urinary tract symptoms: Current concepts.Tzu Chi Med J. 2017 Apr-Jun;29(2):79-83. doi: 10.4103/tcmj.tcmj_20_17. Tzu Chi Med J. 2017. PMID: 28757771 Free PMC article. Review.
-
[Diagnostic work-up of benign prostatic hyperplasia : The German S2e-guideline 2023 part 1].Urologie. 2023 Aug;62(8):805-817. doi: 10.1007/s00120-023-02142-0. Epub 2023 Jul 4. Urologie. 2023. PMID: 37401972 Review. German.
-
Reliability and validity of assessment methods available in primary care for bladder outlet obstruction and benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review.BMJ Open. 2022 Apr 29;12(4):e056234. doi: 10.1136/bmjopen-2021-056234. BMJ Open. 2022. PMID: 35487713 Free PMC article.
Cited by
-
Cost-effectiveness of dutasteride-tamsulosin combination therapy for the treatment of symptomatic benign prostatic hyperplasia: A Canadian model based on the CombAT trial.Can Urol Assoc J. 2013 May-Jun;7(5-6):E393-401. doi: 10.5489/cuaj.12131. Epub 2013 Jun 12. Can Urol Assoc J. 2013. PMID: 23826050 Free PMC article.
-
Adenovirus-mediated delivery of shRNA against bFGF mRNA suppresses growth of cultured human primary prostatic stromal cells.Mol Biol Rep. 2011 Feb;38(2):971-6. doi: 10.1007/s11033-010-0191-2. Epub 2010 Jun 6. Mol Biol Rep. 2011. PMID: 20526813
-
Banana Flower Extract Suppresses Benign Prostatic Hyperplasia by Regulating the Inflammatory Response and Inducing G1 Cell-cycle Arrest.In Vivo. 2018 Nov-Dec;32(6):1373-1379. doi: 10.21873/invivo.11389. In Vivo. 2018. PMID: 30348691 Free PMC article.
-
Quantitative Characterization of the Prostatic Urethra Using MRI: Implications for Lower Urinary Tract Symptoms in Patients with Benign Prostatic Hyperplasia.Acad Radiol. 2021 May;28(5):664-670. doi: 10.1016/j.acra.2020.03.017. Epub 2020 Apr 16. Acad Radiol. 2021. PMID: 32307270 Free PMC article.
-
Therapeutic potential of pomegranate juice-derived nanovesicles in nude mouse benign prostatic hyperplasia (BPH) xenograft model.Sci Rep. 2023 Aug 1;13(1):12427. doi: 10.1038/s41598-023-39511-w. Sci Rep. 2023. PMID: 37528206 Free PMC article.
References
-
- McNeal JG. The prostate gland: morphology and pathobiology. Monogr Urol. 1983;4:3–33.
-
- Berry SJ, Coffey DS, Walsh PC, et al. The development of human prostatic hyperplasia with age. J Urol. 1984;132:474–479. - PubMed
-
- Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of health men: establishment of age-specific reference ranges. JAMA. 1993;270:860–864. - PubMed
-
- Barry MJ, O'Leary MP. The development and clinical utility of symptom scores. Urol Clin N Am. 1995;22:229–307. - PubMed
-
- Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology. 2001;58(suppl 1):5–16. - PubMed
LinkOut - more resources
Full Text Sources
Medical